-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 26, Kelun Pharmaceutical's TROP-2ADC updated its phase I clinical data in the form of an oral report at the CSCO annual meeting
The first human trial of SKB264 includes two parts: Phase I dose escalation and Phase II dose expansion
From: CSCO, official microblog of Kelun Pharmaceutical
The enrolled patients were patients with locally advanced or metastatic solid tumors who had failed multi-line therapy
A total of 17 patients received at least one efficacy evaluation, the overall response rate (ORR) was 41.
From: CSCO, official microblog of Kelun Pharmaceutical
In terms of safety, all 18 patients reported adverse events (AEs).
The early clinical research results of SKB264 showed good tolerability, safety and encouraging anti-tumor activity in patients with metastatic solid tumors.
At the same time, today Kelun has newly declared a new class 1 chemical drug KL290052 capsules.
From: CDE official website